These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 30893643)

  • 1. Genotype-phenotype correlations in pheochromocytoma and paraganglioma: a systematic review and individual patient meta-analysis.
    Crona J; Lamarca A; Ghosal S; Welin S; Skogseid B; Pacak K
    Endocr Relat Cancer; 2019 May; 26(5):539-550. PubMed ID: 30893643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of metastatic pheochromocytoma and paraganglioma in
    Lee H; Jeong S; Yu Y; Kang J; Sun H; Rhee JK; Kim YH
    J Med Genet; 2020 Apr; 57(4):217-225. PubMed ID: 31649053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germline mutations and genotype-phenotype correlations in patients with apparently sporadic pheochromocytoma/paraganglioma in Korea.
    Kim JH; Seong MW; Lee KE; Choi HJ; Ku EJ; Bae JH; Park SS; Choi SH; Kim SW; Shin C; Kim SY
    Clin Genet; 2014 Nov; 86(5):482-6. PubMed ID: 24134185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic Analysis and Clinical Characteristics of Hereditary Pheochromocytoma and Paraganglioma Syndrome in Korean Population.
    Choi H; Kim KJ; Hong N; Shin S; Choi JR; Kang SW; Lee ST; Rhee Y
    Endocrinol Metab (Seoul); 2020 Dec; 35(4):858-872. PubMed ID: 33397040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long intergenic noncoding RNA profiles of pheochromocytoma and paraganglioma: A novel prognostic biomarker.
    Ghosal S; Das S; Pang Y; Gonzales MK; Huynh TT; Yang Y; Taieb D; Crona J; Shankavaram UT; Pacak K
    Int J Cancer; 2020 Apr; 146(8):2326-2335. PubMed ID: 31469413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma.
    Assadipour Y; Sadowski SM; Alimchandani M; Quezado M; Steinberg SM; Nilubol N; Patel D; Prodanov T; Pacak K; Kebebew E
    Surgery; 2017 Jan; 161(1):230-239. PubMed ID: 27839933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SDHB-related pheochromocytoma and paraganglioma penetrance and genotype-phenotype correlations.
    Jochmanova I; Wolf KI; King KS; Nambuba J; Wesley R; Martucci V; Raygada M; Adams KT; Prodanov T; Fojo AT; Lazurova I; Pacak K
    J Cancer Res Clin Oncol; 2017 Aug; 143(8):1421-1435. PubMed ID: 28374168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pseudohypoxia in paraganglioma and pheochromocytoma is associated with an immunosuppressive phenotype.
    Celada L; Cubiella T; San-Juan-Guardado J; Gutiérrez G; Beiguela B; Rodriguez R; Poch M; Astudillo A; Grijalba A; Sánchez-Sobrino P; Tous M; Navarro E; Serrano T; Paja M; Valdés N; Chiara MD
    J Pathol; 2023 Jan; 259(1):103-114. PubMed ID: 36314599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification.
    Crona J; Taïeb D; Pacak K
    Endocr Rev; 2017 Dec; 38(6):489-515. PubMed ID: 28938417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative prediction of metastatic pheochromocytoma and paraganglioma using clinical, genetic, and biochemical markers: A cohort study.
    Park SS; Ahn CH; Lee S; Lee W; Kim WW; Lee YM; Kim SJ; Sung TY; Lee KE; Kim JH; Lee SH; Koh JM
    J Intern Med; 2024 Jul; 296(1):68-79. PubMed ID: 38659304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An overview of 20 years of genetic studies in pheochromocytoma and paraganglioma.
    Buffet A; Burnichon N; Favier J; Gimenez-Roqueplo AP
    Best Pract Res Clin Endocrinol Metab; 2020 Mar; 34(2):101416. PubMed ID: 32295730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local-Regional Recurrence of Pheochromocytoma/Paraganglioma: Characteristics, Risk Factors and Outcomes.
    Cui Y; Ma X; Gao Y; Chang X; Chen S; Lu L; Tong A
    Front Endocrinol (Lausanne); 2021; 12():762548. PubMed ID: 34899602
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Bayley JP; Bausch B; Jansen JC; Hensen EF; van der Tuin K; Corssmit EP; Devilee P; Neumann HP
    J Med Genet; 2023 Jan; 60(1):25-32. PubMed ID: 34750193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic Deregulation of Protocadherin PCDHGC3 in Pheochromocytomas/Paragangliomas Associated With SDHB Mutations.
    Bernardo-Castiñeira C; Valdés N; Celada L; Martinez ASJ; Sáenz-de-Santa-María I; Bayón GF; Fernández AF; Sierra MI; Fraga MF; Astudillo A; Jiménez-Fonseca P; Rial JC; Hevia MÁ; Turienzo E; Bernardo C; Forga L; Tena I; Molina-Garrido MJ; Cacho L; Villabona C; Serrano T; Scola B; Chirivella I; Del Olmo M; Menéndez CL; Navarro E; Tous M; Vallejo A; Athimulam S; Bancos I; Suarez C; Chiara MD
    J Clin Endocrinol Metab; 2019 Nov; 104(11):5673-5692. PubMed ID: 31216007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status.
    Eisenhofer G; Lenders JW; Siegert G; Bornstein SR; Friberg P; Milosevic D; Mannelli M; Linehan WM; Adams K; Timmers HJ; Pacak K
    Eur J Cancer; 2012 Jul; 48(11):1739-49. PubMed ID: 22036874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
    Hadoux J; Favier J; Scoazec JY; Leboulleux S; Al Ghuzlan A; Caramella C; Déandreis D; Borget I; Loriot C; Chougnet C; Letouzé E; Young J; Amar L; Bertherat J; Libé R; Dumont F; Deschamps F; Schlumberger M; Gimenez-Roqueplo AP; Baudin E
    Int J Cancer; 2014 Dec; 135(11):2711-20. PubMed ID: 24752622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germline mutations and genotype-phenotype correlation in Asian Indian patients with pheochromocytoma and paraganglioma.
    Pandit R; Khadilkar K; Sarathi V; Kasaliwal R; Goroshi M; Khare S; Nair S; Raghavan V; Dalvi A; Hira P; Fernandes G; Sathe P; Rojekar A; Malhotra G; Bakshi G; Prakash G; Bhansali A; Walia R; Kamalanathan S; Sahoo J; Desai A; Bhagwat N; Mappa P; Rajput R; Chandrashekhar SR; Shivane V; Menon P; Lila A; Bandgar T; Shah N
    Eur J Endocrinol; 2016 Oct; 175(4):311-23. PubMed ID: 27539324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and molecular markers guide the genetics of pheochromocytoma and paraganglioma.
    Cascón A; Robledo M
    Biochim Biophys Acta Rev Cancer; 2024 Sep; 1879(5):189141. PubMed ID: 38908536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mass spectrometry imaging identifies metabolic patterns associated with malignant potential in pheochromocytoma and paraganglioma.
    Murakami M; Sun N; Greunke C; Feuchtinger A; Kircher S; Deutschbein T; Papathomas T; Bechmann N; William Wallace P; Peitzsch M; Korpershoek E; Friemel J; Gimenez-Roqueplo AP; Robledo M; J L M Timmers H; Canu L; Weber A; R de Krijger R; Fassnacht M; Knösel T; Kirchner T; Reincke M; Karl Walch A; Kroiss M; Beuschlein F
    Eur J Endocrinol; 2021 Jun; 185(1):179-191. PubMed ID: 33983135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SDHD immunohistochemistry: a new tool to validate SDHx mutations in pheochromocytoma/paraganglioma.
    Menara M; Oudijk L; Badoual C; Bertherat J; Lepoutre-Lussey C; Amar L; Iturrioz X; Sibony M; Zinzindohoué F; de Krijger R; Gimenez-Roqueplo AP; Favier J
    J Clin Endocrinol Metab; 2015 Feb; 100(2):E287-91. PubMed ID: 25405498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.